Tacrine

Structural formula
General
Non-proprietary name	Tacrine
other names	Hydroaminacrine; 1,2,3,4-tetrahydroacridine-9-amine ( IUPAC );
Molecular formula	C 13 H 14 N 2
Brief description	octahedral crystals
External identifiers / databases
EC number	206-291-2
ECHA InfoCard	100.005.721
PubChem	1935
ChemSpider	1859
DrugBank	DB00382
Wikidata	Q421076
Drug information
ATC code	N06 DA01
Drug class	Antidementia drugs
Mechanism of action	reversible inhibition of acetylcholinesterase
properties
Molar mass	198.26 g · mol -1
Melting point	183-184 ° C ; 283–284 ° C (hydrochloride);
solubility	soluble in water (hydrochloride)
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
H and P phrases	H: 301-311-315-319-331-335-351
	P: 261-280-301 + 310-305 + 351 + 338-311
Toxicological data	39.8 mg kg −1 ( LD 50 , mouse , oral ) ; 25 mg kg −1 ( LD 50 , mouse , sc ) ; 20 mg kg −1 ( LD 50 , rat , iv ) ; 70 mg kg −1 ( LD 50 , rat , oral ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Tacrine is a reversible inhibitor of acetylcholinesterase and was approved in the USA as the first substance of this group for the treatment of Alzheimer's disease (trade names: Cognex ^® ; Romotal ^® ). The active ingredient leads to an improvement in cognitive performance . It has an indirect parasympathomimetic effect .

However, there was evidence of hepatotoxicity in around 50% of patients .

Individual evidence

↑ ^a ^b ^c ^d ^e ^f ^g Entry on tacrine. In: Römpp Online . Georg Thieme Verlag, accessed on March 22, 2011.
↑ ^a ^b ^c data sheet 9-Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate from Sigma-Aldrich , accessed on April 23, 2011 ( PDF ).
↑ Stefan Förster: Presynaptic effects of cholinesterase inhibitors in the neocortex of humans and rats . Dissertation, University of Freiburg im Breisgau 2005, p. 13.